Will NewLink Genetics’ IDO Inhibitor Improve the Efficacy of AstraZeneca’s Checkpoint Inhibitor in Treating Pancreatic Cancer?

AstraZeneca’s (AZN) checkpoint PD-L1 inhibitor Imfinzi and NewLink Genetics’ (NLNK) IDO inhibitor indoximod will be combined and tested in Phase 2 randomized, placebo-controlled clinical trials together with the standard of care chemotherapy treatment for metastatic pancreatic cancer.

AstraZeneca and NewLink Genetics will jointly fund the phase 2 trial of the combination that  NewLink will be sponsoring  It is a Phase 2  trial that will be conducted to assess the effect of adding AstraZeneca’s product Imfinzi and NewLink’s product indoximod in addition to the . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.